Related references
Note: Only part of the references are listed.Systemic treatment of soft-tissue sarcoma -gold standard and novel therapies
Mark Linch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma
Hege O. Ohnstad et al.
CANCER (2013)
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Christian Tovar et al.
CANCER RESEARCH (2013)
Analysis of DNA Repair-Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response
Maria J. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
Sarah Uboldi et al.
PLOS ONE (2012)
Nilotinib Counteracts P-Glycoprotein-Mediated Multidrug Resistance and Synergizes the Antitumoral Effect of Doxorubicin in Soft Tissue Sarcomas
Victor Hugo Villar et al.
PLOS ONE (2012)
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
Hege O. Ohnstad et al.
BMC CANCER (2011)
The Activity of Trabectedin As a Single Agent or in Combination with Everolimus for Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2011)
Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action
Jordi Martinez-Serra et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2010)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
Samuel Singer et al.
CANCER RESEARCH (2007)
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Christoph R. Muller et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53
Victoria Moneo et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin
Ana B. Herrero et al.
CANCER RESEARCH (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin
MH David-Cordonnier et al.
CHEMISTRY & BIOLOGY (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
